Piscataway, NJ, July 27, 2023–Camber Pharmaceuticals is pleased to announce the addition of Daptomycin for Injection in both 350 mg and 500 mg strengths to its current portfolio.
Daptomycin for Injection is a lipopeptide antibacterial indicated for the treatment of complicated skin and skin structure infections (cSSSI) in adult patients and pediatric patients (1 to 17 years of age).
Daptomycin for Injection is available in 350 mg and 500 mg Single- Dose Vials.
To find out more about Daptomycin 350 mg please visit www.camberpharma.com
To find out more about Daptomycin 500 mg please visit www.camberpharma.com
Camber Pharmaceuticals is a fully integrated pharmaceutical company. Its parent company, Hetero, of Hyderabad, India, is one of the world’s leading API and finished dose manufacturers. Camber is committed to bringing the highest quality generic pharmaceuticals to consumers and improving quality of life through cost-effective medications.
